MHB-088C

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameMHB-088C
Drug Alias NameMHB-088CQLC-5508QLC5508MHB088C
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SuperTopoi payload
Mechanisms of ActionDNA topoisomerase I inhibitorsAnti-CD276
TargetsDNA topoisomerase ICD276 antigen
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMinghui Pharmaceutical Pty Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMinghui Pharmaceutical (Hangzhou) Co LtdMinghui Pharmaceutical Pty LtdQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A